

# US Family Health Plan

## Prior Authorization Request Form for mepolizumab injection (**Nucala**)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be faxed to 855-273-5735

OR

The patient may attach the completed form to the prescription and **mail** it to:  
**Attn: Pharmacy, 77 Warren St, Brighton, MA 02135**

QUESTIONS? **Call 1-877-880-7007**

**Prior authorization approves for up to 300mg for eosinophilic granulomatosis with polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES). Initial approvals expire after twelve months, renewal approvals are indefinite. For renewal of therapy an initial Tricare prior authorization approval is required.**

**Step 1 Please complete patient and physician information (please print):**

<b>1</b>	Patient Name: _____	Physician Name: _____
	Address: _____	Address: _____
	Sponsor ID #: _____	Phone #: _____
	Date of Birth: _____	Secure Fax #: _____

**Step 2 Please complete the clinical assessment:**

**2**

<b>1. Has the patient received this medication under the TRICARE benefit in the last 6 months? Please choose "No" if the patient did not previously have a TRICARE approved PA for Nucala.</b>	<input type="checkbox"/> Yes (subject to verification)  <b>proceed to question 2</b>	<input type="checkbox"/> No  <b>Proceed to question 5</b>
<b>2. What is the patient's diagnosis?</b>	<input type="checkbox"/> severe persistent eosinophilic asthma - <b>Proceed to question 3</b> <input type="checkbox"/> eosinophilic granulomatosis with polyangiitis (EGPA) - <b>Proceed to question 4</b> <input type="checkbox"/> Hypereosinophilic Syndrome (HES) - <b>Proceed to question 4</b> <input type="checkbox"/> Other indication or diagnosis- <b>STOP- Coverage not approved</b>	
<b>3. Has the patient had a positive response to therapy defined as a decrease in asthma exacerbations, improvements in forced expiratory volume in one second (FEV1) or decrease in oral corticosteroid use?</b>	<input type="checkbox"/> Yes <b>Sign and date below</b>	<input type="checkbox"/> No <b>STOP</b> <b>Coverage not approved</b>
<b>4. Has the patient's disease severity improved and stabilized to warrant continued therapy?</b>	<input type="checkbox"/> Yes <b>Sign and date below</b>	<input type="checkbox"/> No <b>STOP</b> <b>Coverage not approved</b>
<b>5. Is the patient currently receiving another immunobiologic (for example, benralizumab [Fasenra], dupilumab [Dupixent] or omalizumab [Xolair])?</b>	<input type="checkbox"/> Yes <b>STOP</b> <b>Coverage not approved</b>	<input type="checkbox"/> No  <b>Proceed to question 6</b>
<b>6. What is the patient's diagnosis?</b>	<input type="checkbox"/> severe persistent eosinophilic asthma - <b>Proceed to question 7</b> <input type="checkbox"/> eosinophilic granulomatosis with polyangiitis (EGPA) - <b>Proceed to question 11</b> <input type="checkbox"/> Hypereosinophilic Syndrome (HES) - <b>Proceed to question 13</b> <input type="checkbox"/> Other indication or diagnosis- <b>STOP- Coverage not approved</b>	

USFHP Prior Authorization Request Form for  
mepolizumab injection (**Nucala**)

<p>7. Is the requested medication being prescribed by an allergist, immunologist, or pulmonologist?</p>	<p><input type="checkbox"/> Yes Proceed to question 8</p>	<p><input type="checkbox"/> No <b>STOP</b> Coverage not approved</p>
<p>8. Does the patient have an eosinophilic phenotype asthma as defined as either:</p> <ul style="list-style-type: none"> <li>• blood eosinophil count of <b>GREATER</b> than or <b>EQUAL</b> to 150 cells/mcL within the past month while on oral corticosteroids OR</li> <li>• blood eosinophil count of <b>GREATER</b> than or <b>EQUAL</b> to 300 cells/mcL within the past year?</li> </ul>	<p><input type="checkbox"/> Yes Proceed to question 9</p>	<p><input type="checkbox"/> No <b>STOP</b> Coverage not approved</p>
<p>9. Has the patient's asthma been uncontrolled despite adherence to optimized medication therapy regimen? <i>Uncontrolled asthma is defined as one of the following: hospitalization for asthma in the past year, OR requiring a course of oral corticosteroids twice in the past year, OR requiring daily high-dose inhaled corticosteroid (ICS) with inability to taper off the ICS.</i></p>	<p><input type="checkbox"/> Yes Proceed to question 10</p>	<p><input type="checkbox"/> No <b>STOP</b> Coverage not approved</p>
<p>10. Has the patient tried and failed an adequate course (3 months) of at least TWO of the following while using a high-dose inhaled corticosteroid:</p> <ul style="list-style-type: none"> <li>• Inhaled long-acting beta agonist (LABA) (for example, Serevent, Striverdi),</li> <li>• long-acting muscarinic antagonist (LAMA) (for example, Spiriva, Incruse),</li> <li>• leukotriene receptor antagonist (for example, Singulair, Accolate, Zyflo)?</li> </ul>	<p><input type="checkbox"/> Yes Sign and date below</p>	<p><input type="checkbox"/> No <b>STOP</b> Coverage not approved</p>
<p>11. Is the patient <b>GREATER THAN</b> or <b>EQUAL TO</b> 18 years of age?</p>	<p><input type="checkbox"/> Yes Proceed to question 12</p>	<p><input type="checkbox"/> No <b>STOP</b> Coverage not approved</p>
<p>12. Is the requested medication being prescribed an allergist, immunologist, pulmonologist, rheumatologist, or hematologist?</p>	<p><input type="checkbox"/> Yes Sign and date below</p>	<p><input type="checkbox"/> No <b>STOP</b> Coverage not approved</p>
<p>13. Has the patient had blood eosinophil count of <b>GREATER</b> than 1,000 cells/mcL in the past year?</p>	<p><input type="checkbox"/> Yes Proceed to question 14</p>	<p><input type="checkbox"/> No <b>STOP</b> Coverage not approved</p>
<p>14. Is the requested medication being prescribed an allergist, immunologist, pulmonologist, rheumatologist, or hematologist?</p>	<p><input type="checkbox"/> Yes Proceed to question 15</p>	<p><input type="checkbox"/> No <b>STOP</b> Coverage not approved</p>
<p>15. Is the patient <b>GREATER THAN</b> or <b>EQUAL TO</b> 12 years of age?</p>	<p><input type="checkbox"/> Yes Sign and date below</p>	<p><input type="checkbox"/> No <b>STOP</b> Coverage not approved</p>

**Step 3** I certify the above is true to the best of my knowledge. Please sign and date:

\_\_\_\_\_ Prescriber Signature

\_\_\_\_\_ Date